Publication:
Sero-surveillance for SARS-CoV-2 infection among healthcare providers in four hospitals in Thailand one year after the first community outbreak

dc.contributor.authorWanitchaya Kittikraisaken_US
dc.contributor.authorPhunlerd Piyarajen_US
dc.contributor.authorApichat Vachiraphanen_US
dc.contributor.authorThanapat Wongrapeeen_US
dc.contributor.authorSomsak Punjasamanvongen_US
dc.contributor.authorTaweewun Hunsawongen_US
dc.contributor.authorChalinthorn Sinthuwattanawiboolen_US
dc.contributor.authorChaniya Leepiyasakulchaien_US
dc.contributor.authorPornsak Yoocharoenen_US
dc.contributor.authorEduardo Azziz-Baumgartneren_US
dc.contributor.authorJoshua A. Motten_US
dc.contributor.authorSuthat Chottanapunden_US
dc.contributor.otherCenters for Disease Control and Preventionen_US
dc.contributor.otherArmed Forces Research Institute of Medical Sciences, Thailanden_US
dc.contributor.otherThailand Ministry of Public Healthen_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherPhramongkutklao College of Medicineen_US
dc.contributor.otherPhaholpolpayuhasena Hospitalen_US
dc.contributor.otherBamrasnaradura Infectious Diseases Instituteen_US
dc.contributor.otherRayong Hospitalen_US
dc.date.accessioned2022-08-04T11:40:39Z
dc.date.available2022-08-04T11:40:39Z
dc.date.issued2021-07-01en_US
dc.description.abstractBackground Thailand was the first country outside China to report SARS-CoV-2 infected cases. Since the detection of the first imported case on January 12th, 2020 to the time this report was written, Thailand experienced two waves of community outbreaks (March-April 2020 and December 2020-March 2021). We examined prevalence of SARS-CoV-2 seropositivity among healthcare providers (HCPs) in four hospitals approximately one year after SARSCoV- 2 first detected in Thailand. By March 2021, these hospitals have treated a total of 709 coronavirus disease 2019 (COVID-19) patients. Methods Blood specimens, collected from COVID-19 unvaccinated HCPs during January-March 2021, were tested for the presence of SARS-CoV-2 immunoglobulin G (IgG) antibodies to nucleocapsid (IgG-nucleocapsid) and spike (IgG-spike) proteins using Euroimmune® enzyme-linked immunosorbent assays. Results Of 600 HCPs enrolled, 1 (0.2%) tested positive for the SARS-CoV-2 IgG-spike antibodies, but not the IgG-nucleocapsid. Conclusion The presence of SARS-CoV-2 IgG antibodies was rare in this sample of HCPs, suggesting that this population remains susceptible to SARS-CoV-2 infection.en_US
dc.identifier.citationPLoS ONE. Vol.16, No.7 July (2021)en_US
dc.identifier.doi10.1371/journal.pone.0254563en_US
dc.identifier.issn19326203en_US
dc.identifier.other2-s2.0-85110169960en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/79340
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85110169960&origin=inwarden_US
dc.subjectMultidisciplinaryen_US
dc.titleSero-surveillance for SARS-CoV-2 infection among healthcare providers in four hospitals in Thailand one year after the first community outbreaken_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85110169960&origin=inwarden_US

Files

Collections